Catalyst Pharmaceuticals to Report First Quarter 2026 Financial Results on May 11, 2026
Rhea-AI Summary
Catalyst Pharmaceuticals (Nasdaq: CPRX) will release first quarter 2026 financial results after market close on May 11, 2026 and will host a conference call and webcast on May 12, 2026 at 8:30 AM ET to discuss results and provide a business update.
The webcast will be available in the Investors section of the company's website and a replay will remain accessible for at least 30 days.
Positive
- None.
Negative
- None.
News Market Reaction – CPRX
In the Apr 28 session, CPRX gained 0.58%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 11 | Earnings date notice | Neutral | -1.4% | Announced timing for Q4 and full-year 2025 results and follow-up call. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Limited tag-specific history: the prior earnings date announcement saw a modest -1.4% move, indicating slight negative drift around scheduling releases.
Over recent months, Catalyst reported record 2025 revenues of $589.0 million with strong contributions from FIRDAPSE and AGAMREE and guided 2026 revenues to $615–$645 million. It also announced a $200 million share repurchase program and hosted investor-focused events, including conference participation and advocacy initiatives. The prior earnings date release for Q4 and full-year 2025 preceded record results and a -1.4% one-day move, framing today’s Q1 2026 scheduling in a context of strong recent execution.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The Company will Host a Conference Call and Webcast on May 12, 2026, at 8:30 AM ET
CORAL GABLES, Fla., April 28, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its first quarter 2026 financial results after the market close on Monday, May 11, 2026.
Catalyst's management team will host a conference call and webcast on Tuesday, May 12, 2026, at 8:30 AM ET to discuss the Company's financial results and provide a business update.
| Conference Call & Webcast Details | |
| Date: | May 12, 2026 |
| Time: | 8:30 AM ET |
| US/Canada Dial-in Number: | (855) 761-5600 |
| International Dial-in Number: | (646) 307-1097 |
The webcast will be accessible under the Investors section on the Company's website at www.catalystpharma.com. A webcast replay will be available on Catalyst’s website for at least 30 days following the date of the event.
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence, which remains the cornerstone of our commercial strategy, while continuously evaluating strategic opportunities to expand our global footprint. Catalyst, headquartered in Coral Gables, Fla., has been recognized by Forbes as one of America’s Most Successful Company in 2023, 2024, and 2025, and on the 2025 Deloitte Technology Fast 500™ list as one of North America’s Fastest-Growing Companies.
For more information, please visit Catalyst's website at www.catalystpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2025 and its subsequent filings with the U.S. Securities and Exchange Commission (“SEC”), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.
Source: Catalyst Pharmaceuticals, Inc.
Investor Contact Melissa Kendis, Catalyst Pharmaceuticals, Inc. (305) 420-3200 IR@catalystpharma.com Media Contact Ignacio Guerrero-Ros, Ph.D., Russo Partners, LLC (646) 249-6817 Ignacio.Guerrero-Ros@russopartnersllc.com